Please wait while the formulary information is being retrieved.
TRIHEXYPHENIDYL HCL (TRIHEXYPHENIDYL HCL)
- Idiopathic parkinsonism
- Arteriosclerotic parkinsonism
- Drug-induced extrapyramidal reaction
- Parkinsonism
- Postencephalitic parkinsonism
trihexyphenidyl 0.4 mg/mL oral elixir
- 5 milliliters (2 mg) by oral route 3 times per day
Arteriosclerotic parkinsonism
- 5 milliliters (2 mg) by oral route 3 times per day
- 5 milliliters (2 mg) by oral route 4 times per day
Drug-induced extrapyramidal reaction
- 2.5 milliliters (1 mg) by oral route once daily
- 2.5 milliliters (1 mg) by oral route 2 times per day
- 2.5 milliliters (1 mg) by oral route 3 times per day
- 2.5 milliliters (1 mg) by oral route 4 times per day
- 5 milliliters (1 mg) by oral route once daily
- 5 milliliters (2 mg) by oral route 2 times per day
- 5 milliliters (2 mg) by oral route 3 times per day
- 5 milliliters (2 mg) by oral route 4 times per day
- 10 milliliters (4 mg) by oral route 3 times per day
- 10 milliliters (4 mg) by oral route once daily
Idiopathic parkinsonism
- 5 milliliters (2 mg) by oral route 3 times per day
- 5 milliliters (2 mg) by oral route 4 times per day
Parkinsonism
- 5 milliliters (2 mg) by oral route 3 times per day
- 5 milliliters (2 mg) by oral route 4 times per day
- 10 milliliters (4 mg) by oral route 3 times per day
Postencephalitic parkinsonism
- 10 milliliters (4 mg) by oral route 3 times per day
- pramlintide
- Symlinpen 120
- Symlinpen 60
Contraindicated
- K-tab
- Klor-con
- Klor-con 10
- Klor-con M10
- Klor-con M15
- Klor-con M20
- Medi-lyte
- potassium chloride
- potassium citrate
- potassium Cl-calcium phos-mag
- sodium Cl-potassium chloride
- Thermotabs
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
Severe
Moderate
- Adasuve
- chlorpromazine
- Compazine
- Compro
- fluphenazine decanoate
- fluphenazine HCl
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- loxapine
- loxapine succinate
- Loxitane
- perphenazine
- perphenazine-amitriptyline
- Phenadoz
- Phenergan
- prochlorperazine
- prochlorperazine Edisylate
- prochlorperazine maleate
- promethazine
- Promethazine Vc
- Promethazine Vc-codeine
- promethazine-codeine
- promethazine-DM
- promethazine-phenyleph-codeine
- promethazine-phenylephrine
- Promethegan
- thioridazine
- trifluoperazine
- Achalasia of esophagus
- Angle-closure glaucoma
- Atony of colon
- Gastrointestinal obstruction
- Hemorrhagic shock
- Paralytic ileus
- Severe ulcerative colitis
- Thyrotoxicosis
- Toxic megacolon
- Urinary retention
- Urinary tract obstruction
Contraindicated
- Autonomic neuropathy
- Benign prostatic hyperplasia
- Chronic heart failure
- Clostridium difficile infection
- Coronary artery disease
- Fever
- Gastric ulcer
- Gastroenteritis due to shigella
- Gastroesophageal reflux disease
- Hiatal hernia
- Hypotension
- Myasthenia gravis
- Tardive dyskinesia
- Ulcerative colitis
Severe
Moderate
- Cardiac arrhythmia
- Chronic obstructive pulmonary disease
- Disease of liver
- Dysuria
- Hypertension
- Kidney disease with reduction in GFR
- Open angle glaucoma
TRIHEXYPHENIDYL HCL (TRIHEXYPHENIDYL HCL)
- Idiopathic parkinsonism
- Arteriosclerotic parkinsonism
- Drug-induced extrapyramidal reaction
- Parkinsonism
- Postencephalitic parkinsonism
- None
- Blurred vision
- Constipation
- Decreased sweating
- Drowsy
- Dry nose
- Dry throat
- Dysuria
- Excitement
- Nausea
- Photophobia
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute confusion
- Ocular hypertension
- Skin rash
Less Severe
- Abdominal pain with cramps
- Cramps
- False sense of well-being
- General weakness
- Headache disorder
- Hypesthesia
- Memory impairment
- Mouth irritation
- Nervousness
- Orthostatic hypotension
- Sore tongue
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Trihexyphenidyl
No safety and efficacy.
- 1 Day – 18 Years
- No safety and efficacy.
Trihexyphenidyl
- Severity Level:
C
- Additional Notes: Insufficient human and animal data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Trihexyphenidyl
Insufficient data available; may inhibit lactation
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; may inhibit lactation |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
Trihexyphenidyl
General-AVOID; not recommended for prevention of EPS from antipsychotics; more effective treatments available for Parkinson Disease. Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause. Ocular-Avoid use with narrow-angle glaucoma.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
Precaution Exists
None
No Known Risk
None
- None
| Arteriosclerotic parkinsonism | |
| G21.4 | Vascular parkinsonism |
| Drug-induced extrapyramidal reaction | |
| G25 | Other extrapyramidal and movement disorders |
| G25.7 | Other and unspecified drug induced movement disorders |
| G25.70 | Drug induced movement disorder, unspecified |
| G25.79 | Other drug induced movement disorders |
| G25.8 | Other specified extrapyramidal and movement disorders |
| G25.89 | Other specified extrapyramidal and movement disorders |
| G25.9 | Extrapyramidal and movement disorder, unspecified |
| Idiopathic parkinsonism | |
| G20 | Parkinson's disease |
| Parkinsonism | |
| G20 | Parkinson's disease |
| G21 | Secondary parkinsonism |
| G21.2 | Secondary parkinsonism due to other external agents |
| G21.3 | Postencephalitic parkinsonism |
| G21.4 | Vascular parkinsonism |
| G21.8 | Other secondary parkinsonism |
| G21.9 | Secondary parkinsonism, unspecified |
| Postencephalitic parkinsonism | |
| G21.3 | Postencephalitic parkinsonism |
| 0-9 | A-Z |
|---|---|
| G20 | Parkinson's disease |
| G20 | Parkinson's disease |
| G21 | Secondary parkinsonism |
| G21.2 | Secondary parkinsonism due to other external agents |
| G21.3 | Postencephalitic parkinsonism |
| G21.3 | Postencephalitic parkinsonism |
| G21.4 | Vascular parkinsonism |
| G21.4 | Vascular parkinsonism |
| G21.8 | Other secondary parkinsonism |
| G21.9 | Secondary parkinsonism, unspecified |
| G25 | Other extrapyramidal and movement disorders |
| G25.7 | Other and unspecified drug induced movement disorders |
| G25.70 | Drug induced movement disorder, unspecified |
| G25.79 | Other drug induced movement disorders |
| G25.8 | Other specified extrapyramidal and movement disorders |
| G25.89 | Other specified extrapyramidal and movement disorders |
| G25.9 | Extrapyramidal and movement disorder, unspecified |
Formulary Reference Tool